Drug class
18F-labelled prostate-specific membrane antigen (PSMA) PET radiotracer; diagnostic imaging agent
Mechanism of action
Binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. PET imaging detects tracer distribution to localise PSMA-expressing prostate cancer lesions; it is a diagnostic radiopharmaceutical, not a therapeutic PSMA inhibitor.
General use cases
- PET imaging of PSMA-positive lesions in men with prostate cancer to localise disease for initial staging or suspected recurrence, in conjunction with other diagnostic evaluations under the US PYLARIFY-like? specific product label; use only for the approved product indication and patient group
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
